These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 14648339

  • 1. Enalapril dosage in steroid-resistant nephrotic syndrome.
    Bagga A, Mudigoudar BD, Hari P, Vasudev V.
    Pediatr Nephrol; 2004 Jan; 19(1):45-50. PubMed ID: 14648339
    [Abstract] [Full Text] [Related]

  • 2. Enalapril: antiproteinuric effect in children with nephrotic syndrome.
    Lama G, Luongo I, Piscitelli A, Salsano ME.
    Clin Nephrol; 2000 Jun; 53(6):432-6. PubMed ID: 10879662
    [Abstract] [Full Text] [Related]

  • 3. Combined renin angiotensin blockade in childhood steroid-resistant nephrotic syndrome.
    Supavekin S, Surapaitoolkorn W, Tancharoen W, Pattaragarn A, Sumboonnanonda A.
    Pediatr Int; 2012 Dec; 54(6):793-7. PubMed ID: 22621380
    [Abstract] [Full Text] [Related]

  • 4. Cyclosporine in the treatment of childhood idiopathic steroid resistant nephrotic syndrome: a single centre experience in Nigeria.
    Ladapo TA, Esezobor CI, Lesi FE.
    Pan Afr Med J; 2016 Dec; 25():258. PubMed ID: 28293374
    [Abstract] [Full Text] [Related]

  • 5. Enalapril and prednisone in children with nephrotic-range proteinuria.
    Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA.
    Pediatr Nephrol; 2000 Oct; 14(12):1088-91. PubMed ID: 11045392
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of enalapril in the treatment of steroid resistant idiopathic nephrotic syndrome.
    Prasher PK, Varma PP, Baliga KV.
    J Assoc Physicians India; 1999 Feb; 47(2):180-2. PubMed ID: 10999084
    [Abstract] [Full Text] [Related]

  • 7. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, Nakhoul N, Hoffman A, Abassi Z.
    Am J Physiol Renal Physiol; 2008 Mar; 294(3):F628-37. PubMed ID: 18094029
    [Abstract] [Full Text] [Related]

  • 8. Antiproteinuric effects of enalapril and losartan: a pilot study.
    White CT, Macpherson CF, Hurley RM, Matsell DG.
    Pediatr Nephrol; 2003 Oct; 18(10):1038-43. PubMed ID: 12920631
    [Abstract] [Full Text] [Related]

  • 9. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA, Cockram CS.
    Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
    [Abstract] [Full Text] [Related]

  • 10. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
    Nakhoul F, Ramadan R, Khankin E, Yaccob A, Kositch Z, Lewin M, Assady S, Abassi Z.
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F880-90. PubMed ID: 15942045
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome.
    Milliner DS, Morgenstern BZ.
    Pediatr Nephrol; 1991 Sep; 5(5):587-90. PubMed ID: 1911144
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
    Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A.
    Am J Kidney Dis; 2009 May; 53(5):760-9. PubMed ID: 19268410
    [Abstract] [Full Text] [Related]

  • 13. Adequate clinical control of congenital nephrotic syndrome by enalapril.
    Guez S, Giani M, Melzi ML, Antignac C, Assael BM.
    Pediatr Nephrol; 1998 Feb; 12(2):130-2. PubMed ID: 9543371
    [Abstract] [Full Text] [Related]

  • 14. [Multicenter survey of diagnostic and therapeutic status in Chinese childhood patients with steroid-sensitive, relaping/steroid-dependent nephrotic syndrome].
    Working Group For National Survey On Status Of Diagnosis And Treatment Of Childhood Renal Diseases.
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):194-200. PubMed ID: 24824389
    [Abstract] [Full Text] [Related]

  • 15. Treatment with candesartan combined with angiotensin-converting enzyme inhibitor for immunosuppressive treatment-resistant nephrotic syndrome after allogeneic stem cell transplantation.
    Osugi Y, Yamada H, Hosoi G, Noma H, Ikemiya M, Ishii T, Sako M.
    Int J Hematol; 2006 Jun; 83(5):454-8. PubMed ID: 16787879
    [Abstract] [Full Text] [Related]

  • 16. Enalapril prevents fatty liver in nephrotic rats.
    Toblli JE, Ferder L, Stella I, Angerosa M, Inserra F.
    J Nephrol; 2002 Jun; 15(4):358-67. PubMed ID: 12243364
    [Abstract] [Full Text] [Related]

  • 17. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [Abstract] [Full Text] [Related]

  • 18. Long-term therapy with enalapril in patients with nephrotic-range proteinuria.
    Proesmans W, Wambeke IV, Dyck MV.
    Pediatr Nephrol; 1996 Oct; 10(5):587-9. PubMed ID: 8897561
    [Abstract] [Full Text] [Related]

  • 19. Antiproteinuric action of amiloride in paediatric patient with corticoresistant nephrotic syndrome.
    Liern M, Colazo A, Vallejo G, Zotta E.
    Nefrologia (Engl Ed); 2021 Oct; 41(3):304-310. PubMed ID: 33722403
    [Abstract] [Full Text] [Related]

  • 20. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
    Kwinta-Rybicka J, Wilkosz K, Wierzchowska-Słowiacze EK, Ogarek I, Moczulska A, Stec Z, Pełkowska A, Sancewicz-Pach K, Pietrzyk JA.
    Przegl Lek; 2006 Oct; 63 Suppl 3():44-8. PubMed ID: 16898486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.